Emerging life sciences companies grabbing more in government grants
More emerging life science companies have found life in the form of federal
Small Business Innovation Research grants.
Bioscience
Articles
Lilly cancels trials for experimental MS drug
Eli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
Dow Agrosciences introduces genetically modified corn seed
Even after a string of acquisitions, Dow AgroSciences is a bit player in the seed business. But the new genetically
modified corn it developed with St. Louis-based giant Monsanto Co. finally provides the breakthrough product that could grow
its seed sales substantially.
Stem cell discovery promises health care revolution
Scientists are using a new stem-cell technique that may someday revolutionize care for disorders as diverse as diabetes, Alzheimer’s
disease and muscular dystrophy.
Indiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individuals
Indiana is becoming not only a hotbed of “pharmacogenomics” research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
Executives make many trips to Washington to argue for 14 years of sales exclusivity for new drugs made from cells
Eli Lilly & Co. executives are making many trips to Washington to argue for 14 years of sales exclusivity for new drugs made
from cells.
Biotech push may help offset generic competition; some analysts skeptical
Lilly executives want to make biotech their top focus.
Report sees jackpot with BioCrossroads, but expert sees obstacles
Three months after launching an initiative to boost drug-development firms in Indiana, officials at BioCrossroads have written
a report that attempts to show in detail the vast market opportunity they see.
IU takes statewide approach to life sciences pitch
For the last two months, two academics at Indiana University and Purdue University have been discussing how the institutions
can work together to rev up research in medicine and life sciences and, in the process, boost Indiana’s economy.
Ex-Lilly execs take on diabetes with Carmel startup
Four former top scientists at Eli Lilly and Co. have formed a Carmel-based company to develop diabetes therapies–a venture observers say has the potential to become the kind of blockbuster success BioCrossroads was built to stimulate.
Ex-prosecutor’s lab biz builds network of government clients
Labs are nearing capacity at Strand Analytical Laboratories, which provides forensic and paternity DNA testing. In the second year of Scott Newman’s business, the former prosecutor predicts 2007 revenue will reach $4 million.